Yes, CAPA programs are examined during drug quality audits in Japan. Regulatory authorities, such as the Pharmaceuticals and Medical Devices Agency (PMDA), assess CAPA effectiveness to ensure compliance with Good Manufacturing Practices (GMP). These evaluations focus on identifying root causes, implementing corrective actions, and preventing recurrence to maintain product quality and safety.
